


Total Synthesis of Platensimycin


Zhensheng Ding

October 19 2007



- Nicolaou, K. C. *Angew. Chem. Int. Ed.*, **2006**, *45*, 7086-90
Nicolaou, K. C. *Angew. Chem. Int. Ed.*, **2007**, *46*, 3942-5
Nicolaou, K. C. *Angew. Chem. Int. Ed.*, **2007**, *46*, 4712-4
Nicolaou, K. C. *Chem. Commun.*, **2007**, 1922-3
Zou, Y.; Snider, B. *Org. Lett.*, **2007**, *9*, 1825-8
Heretsch, P.; Giannis, A. *Synthesis* **2007**, 2614-6
Ghosh, A. *Org. Lett.*, **2007**, *9*, 4013-6
Kaliappan, K. P. and Ravikumar, V. *Org. Lett.*, **2007**, *9*, 2417-9
Li, P.; Yamamoto, H. *J. Am. Chem. Soc.* **2007**, *129*, 9534-5
Mulzer, J. *Angew. Chem. Int. Ed.* **2007**, *46*, 8074-5
Corey, E. J. *Org. Lett.*, **2007**, xxxx


Super Drug: Platensimycin and Its Structure Features




Tetracyclic motif
Cage-like
6 chiral centers
3 tertiary carbons
Ether linkage

Tetra-substituted resorcinol
Amino acid

Outline







Summary: Enone Synthesis from Ketone




Nicolaou
Corey


Summary: Enone Synthesis from Ketone






Nicolaou's Racemic Synthesis: Retrosynthesis




Synthesis




Synthesis






Nicolaou's Asymmetric Synthesis: Retrosynthesis



Nicolaou's Asymmetric Synthesis



Summary

Pathway a) was able to scale up; expensive and toxic reagents; multiple step.

$\text{Cr}(\text{CO})_6$: \$266/ 50g, toxic and carcinogen; BuLi: \$107/ 800mL (2.5M), corrosive, highly sensitive to air


Pathway b) Moderate yield, one step synthesis; hard to purify, not suitable for old VAPOL synthesis.

Purpose: To find an efficient way to prepare both ligands with inexpensive starting materials.


How to optimize pathway b) ?

- 1) Solvent---must be high bp, inert, easily removable;
- 2) Lower the reaction temperature (base);
- 3) None-toxic reagents;
- 4) More efficient


Nicolaou's Asymmetric Synthesis: Another Pathway




Nicolaou's Analogues Synthesis: Adamantaplatensimycin



(-)-1: platensimycin



(-)-2




(+)2


Table 1: Minimum inhibitory concentration values ($\mu\text{g mL}^{-1}$) of (-)-2, (+)-2, and (\pm)-2 against methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus faecium* (VREF), and *E. coli*.^[a]

	(+)-2	(-)-2	(\pm)-2	(-)-1 ^[b]	(\pm)-1 ^[c]
MRSA	> 88	1.3–1.8	2.6–3.6	0.2–0.4	0.4–0.8
VREF	> 88	1.3–1.8	2.6–3.6	0.4–0.8	0.8–1.6
<i>E. coli</i>	> 88	> 88	> 88	> 88	> 88


Nicolaou's Analogues Synthesis: Adamantaplatensimycin




Resolution of **12**




Outline




Yamamoto: Asymmetric DA-Robinson Annulation Sequence






Yamamoto: Asymmetric DA-Robinson Annulation Sequence



Yamamoto: Asymmetric DA-Robinson Annulation Sequence




Yamamoto: Asymmetric DA-Robinson Annulation Sequence



leading to **9**

9


v.s.



leading to **9'**


9 Me

Ghosh: Intramolecular Diels-Alder Reaction Retrosynthesis




- a) Srikrishna, A.; Hemamalini, P. *J. Org. Chem.* **1990**, 55, 4883. (b) Weinges, K.; Reichert, H. *Synlett* **1991**, 785.
(c) Weinges, K.; et al *Liebigs Ann. Chem.* **1993**, 403. (d) Weinges, K. et al *Chem. Ber.* **1994**, 127, 549.


Ghosh: Intramolecular Diels-Alder Reaction




Continued...




Outline



Retrosynthetic Analysis: Summary





Corey's Synthesis




Corey's Synthesis

Li in liquid $\text{NH}_3\text{-THF}$ at $-78\text{ }^\circ\text{C}$,



Caron-ring construction first



Nicolaou, K. C. *Chem. Commun.*, **2007**, 1922-3

Zou, Y.; Snider, B. *Org. Lett.*, **2007**, 9, 1825-8


Kaliappan, K. P. and Ravikumar, V. *Org. Lett.*, **2007**, 9, 2417-9

Kaliappan's synthesis


Nicolaou's synthesis

Snider's synthesis


Nicolaou's Synthesis




Kaliappan's Retrosynthesis



Kaliappan's Synthesis




Snider's Retrosynthesis




Caron-ring construction first

Snider's Synthesis



Mulzer's Synthesis




1) Mulzer, J. *Angew. Chem. Int. Ed.* **2007**, *46*, 8074-5

2) D. J. Beames, T. R. Klose, L. N. Mander, *Aust. J. Chem.* 1974, *27*, 1269.


3) P. Anantha Reddy, G. S. Krishna Rao, *Indian J. Chem. Sect. B* 1981, *20*, 100.

Mulzer's Synthesis



conditions: a) MeMgI, 1HF, -78°C, 4 h (71% brsm); b) NBS, (BzO)₂, CCl₄, reflux, 90 min (75%); c) NaOMe, THF, 0°C, 30 min (80%); d) cat. [Ir(cod)Py(PCy₃)]PF₆, H₂ (1 bar), CH₂Cl₂, over night, (78% brsm), **12/11** = 1.3:1; alternatively: Pd/C (5%), KOH, EtOH, H₂ (1 bar), 3 h (90%), **12/11** = 1:2; e) HIO₃·DMSO, DMSO, cyclohexene, 50°C, 8 h (60%). brsm = based on recovered starting material, NBS = N-bromosuccinimide, Bz = benzoyl, cod = cyclooctadiene, Py = pyridine, Cy = cyclohexyl, DMSO = dimethyl sulfoxide.

Conclusions



- 1) Nicolaou's racemic: 10 steps, 11%;
- 2) Nicolaou's asymmetric: 16 steps, 5.6% using chiral catalysis; 11 steps, chiral auxiliary;
- 3) Snider's: 7 steps + equilibration + one step for conversion of a diastereomer, 32%;
- 4) Mulzer's: protecting-group-free; 5 steps from **7** (overall yield 20%);
- 5) Corey's: 14 steps, 25.6%; (calculated by meeeee!)
- 6) Kaliappan's: 13 steps, 5.6%; (calculated by meeeee!)
- 7) Yamamoto's: 8 steps + one step for conversion of a diastereomer, 18% (calculated by me! not sure!!!)

